• ≥ 18 years of age with hepatobiliary cancers and SEA American self-report (they or their family members are from/had been from Cambodia, Laos, or Vietnam) are eligible.
• Newly diagnosed hepatobiliary cancers.

• < 18 years of age. 

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/2/22. Questions regarding updates should be directed to the study team contact.

• 18 years of age and older.
• Without current, confounding cardiorespiratory, metabolic, or musculoskeletal conditions.  

• < 18 years of age. 

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/14/23. Questions regarding updates should be directed to the study team contact.

• Candidate on the kidney transplant waiting list for more than 3 months..
• 18 years of age or older.
• English-speaking.

• Non-English speaking.
• < 18 years of age.
• Patients who choose to opt out of research.
• Unable to provide informed consent.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 2/6/23. Questions regarding updates should be directed to the study team contact.

• Any patient for whom we are able to obtain consent prior to their procedure or after their procedure in the intensive care unit.
• Patient must have a PA catheter, or a CCO/Flo Trak for the procedure.
• Is presenting for a procedure in which CPB will be required.
• Is considered high risk for VS.
• Patient considered to be at high risk for the development of VS will be identified per the guidelines developed by Levin et al. This includes any patient:
  • With pre-CPB vasopressor requirement(s); or
  • On pre-operative ACE, or beta-blocker or calcium channel blocker therapy; or
  • With a euroSCORE > 6; or
  • Presenting for pericardiectomy, aneurysm surgery, LVAD surgery or heart transplant, CABG or valve surgery other than a single mitral valve repair.
• Has no contraindications to arterial line or PA catheter placement
• Patient must fall into the defined parameters below for the majority of measurements over a 30 minute period (ex: 3 out of 5 measurements or 6 of 10, etc.):
  • Develops high-dose vasopressors for 30 min or longer and refractory hypotension consistent with VS within 24 hours of coming off CPB;
  • “High-dose vasopressor” will be defined as:
    • Norepinephrine infusion ≥ 0.1 mcg/kg/min; and/or
    • Dopamine infusion ≥ 15mcg/kg/min; and/or
    • Epinephrine infusion ≥ 0.1mcg/kg/min; or
  • Norepinephrine equivalent infusion of ≥ 0.1mcg/kg/min.
  • “Hypotension consistent with VS” will be defined as:
    • MAP< 75 mmHg via arterial line monitor.
• Cardiac index > 2.3L/min/m^2 via PA catheter monitor.
• If at the time study drug arrives, the patient who previously met criteria has fallen out, they must once again meet requirements only one time before the drug is given.

• Age < 18 years old.
• Known pregnancy or patients without a documented pregnancy test if not menopausal.
• Known prior anaphylactic or allergic reaction to B12a.
• CKD stage 4 or worse (GFR < 30 ml/min) before study drug administration.
• ECMO (extracorporeal membrane oxygenation) or IABP (intra-aortic balloon pump)prior to study consent and post cardiopulmonary bypass.
• Patients currently on cardiopulmonary bypass.
• Circumstance for which the safety of the patient could be jeopardized by continued adherence to the study protocol.

Eligibility last updated 1/11/22. Questions regarding updates should be directed to the study team contact.

• Primary liver diseases.
• Diagnosis of suspected kidney function insufficient with laboratory test.
• Age ≥ 18 years.

• Patients with kidney congenital diseases, such as renal agenesis, hypoplasia, horseshoe kidney, abnormal location kidney, etc.
• Patients with transplant kidney.
• Patients with HIV infection (lower immune activity).
• History of liver transplantation or hepatic resection.
• Absolute contraindications to MRI including pacemaker, AICD device, cochlear implant, VP shunt, aneurysm clip, a deep brain stimulator, and severe claustrophobia.
• Women who are pregnant or breastfeeding.
• Any severe medical condition that, in the opinion of the Principal Investigator, would serve as exclusion criteria for study enrollment.

• Patients ≥ 18 years of age with Hepatocellular Carcinoma (HCC) and SEA American self-report (they or their family members are from/had been from Cambodia, Laos, or Vietnam) are eligible.
• Diagnosis of HCC.

• < 18 years of age. 

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 9/23/22. Questions regarding updates should be directed to the study team contact.

• Specimens will be collected from all consenting adults (age ≥ 18 years) with confirmed or suspected AML or ALL that represents a new diagnosis, a recurrence, or a progression from well recognized harbingers of acute leukemia.

Inclusion Criteria

• Clinical diagnosis of COPD
• Age ≥40 years
• Current or previous smoker (≥10 packs per year)
• Confidence in using the proposed PR system
• English or Spanish language fluency

Exclusion Criteria

• Unable or unwilling to do Rehabilitation due to physical conditions

• Hispanic adults (age 18 or older).
• Speak Spanish fluently.
• Identify as a survivor or co-survivor of breast, cervical, or colorectal cancer.
• Have received all the recommended COVID-19 vaccinations for their age group (we will be in close quarters during the DST workshop and want to protect any participants who may be immunocompromised after receiving cancer treatment).

• People younger than 18 years old.
• Non-Hispanic individuals.
• Hispanic individuals who do NOT speak Spanish.
• Individuals who do NOT identify as a survivor or co-survivor of breast, cervical, or colorectal cancer.
• Individuals who have not received a COVID-19 vaccination.

Eligibility last updated 8/2/22. Questions regarding updates should be directed to the study team contact

• Age 12-25
• Patients in the 2-day Pediatric Pain Rehabilitation Program

• Don’t speak English as their first language

• All adult patients (≥ 18 years old) who are referred for invasive hemodynamic assessment of chronic dyspnea.
• Patients who have the capacity to understand and consent for the research study.

• Patients with known interstitial lung disease or pulmonary fibrosis.

• Men and women.
• Ages ≥ 18 to ≤ 65 years old.
• Able to tolerate lying motionless, flat on one's back in an MRI scanner for no more than 60 minutes.
• Patients affected by Autosomal Dominant Polycystic Kidney Disease (ADPKD).

• No contraindication to MRI.
• No implanted devices within the body (shunts, clips, plates, etc.).
• No dental braces or retainer wires.

• Age ≥ 18 years old.
• Capable of giving consent.
• Established diagnosis of Multiple Sclerosis according to McDonald Criteria (2018). Patients may be diagnosed with any of the conventional phases of MS, primary progressive, relapsing remitting, secondary progressive etc.
• Willing to participate in a 7T MRI examination within a few days of their clinical 3T or 1.5T examination.

• Age < 18 years old.
• Any metallic implant, device implant, ventriculoperitoneal shunt, cardiac valve, pacemaker which would constitute a contraindication to 7T imaging.
• Previous craniotomy.
• Permanent facial makeup (for brain scanning).
• Suffer from claustrophobia.
• Pregnancy.
• Fever / elevated temperature.

Eligibility last updated 7/14/22. Questions regarding updates should be directed to the study team contact.

• Male or female patients, aged 0 to 100 with a vascular tumor or malformation.
• Able to provide Informed Consent (or parental ability to provide informed consent if under age 18).
• Have a Mayo Clinic Number.

• Individuals who are unable to sign consent (e.g., mentally challenged, those declared legally incompetent, non-english speaking) or whose parents are unable to provide informed consent if under age 18.

• Women of reproductive age, 18 – 49 years.
• Seen for clinical care by an obstetrician/gynecologist or cardiologist; advanced practice nurse or physician assistant working in the selected practice.

• Complex congenital heart disease (single ventricle physiology, complex cardiac surgery or significant shunts with cardiac structural changes).
• Significant conduction abnormalities.

• Subject is at least 18 years of age.
• Subjects is indicated for a routine ultrasound examination at the site, including with or without examination with contrast.
• Subject is willing and capable of providing informed consent and participating in this study.

• Subjects who are pregnant will be excluded from the study.
• Subjects with a limited capacity to consider being scanned on an additional ultrasound system will be excluded. 

• New patients to a PHA Care Center with either newly diagnosed or established PAH or CTEPH (within 6 months of first outpatient visit at the PHCC).
• Informed consent for data to be abstracted and included in the PHAR provided by the patient or guardian.
• Able to understand and speak either English or Spanish.

• Any exception to the Inclusion Criteria above.

• Mayo Clinic patients with suspected Familial Hypercholesterolemia (FH).
• Age ≥ 18 years.
• LDL cholesterol ≥ 190 mg/dl.
• Capable of providing informed consent.

• Lack of research authorization.
• Unable to provide informed consent.

• Patients had to be seen by a health care provider at least once at the Family Medicine and Primary Care Internal Medicine clinics of Mayo Clinic in Rochester, MN or the Mayo Clinic Health System during the study time. 
• Patients had to be empaneled to a primary care provider.
• Ability to give informed consent.
• Ability to read and speak the English language.
• Age 65 or older.

• Patients that had not to be seen by a health care provider during the study time.
• Any participant who refused medical record review.
• Incarcerated individuals.
• Hospice enrollment.
• Memory Care residents.
• Major Neurocognitive disorder (severe and moderate dementia).

• Subject is ≥ 18 years old.
• Subject is indicated and scheduled for an elective, non-emergent ERCP.
• Subject is willing and able to give informed consent and HIPAA authorization.

• Subject has altered pancreaticobiliary anatomy including:
• Billroth II;
• Roux-en-Y gastric bypass;
• Loop gastric bypass;
• Post-Whipple;
• Roux-en-Y hepaticojejunostomy.
• Subject requires an emergency ERCP (emergent decompression procedure within 6-12 hours of presentation to prevent life-threatening sequelae).
• Subject has one or more of the following severe co-morbid conditions:
• Morbid obesity (BMI ≥ 40);
• Unstable cardiopulmonary conditions;
• Severe and uncorrectable coagulopathy;
• Severe and uncorrectable thrombocytopenia.
• Subject has clinically significant esophageal, pyloric or duodenal strictures.
• Subject is pregnant or female with reproductive capability who is unwilling to have a pre-procedure pregnancy test and use birth control.
• Subject is actively taking an anticoagulant or antiplatelet agent other than aspirin.
• Subject, in the opinion of the Investigator, has a severe comorbidity, poor general physical/mental health and/or a condition that will not allow the subject to be a good study candidate.

Inclusion Criteria:

• Age ≥ 18 and < 60 years.
• Diagnosed with IBD (Crohn’s disease, ulcerative colitis, or indeterminate colitis).
• Living in the United States.  

• Patients with current ostomies or ileal pouches.
• Currently in a medication trial for non-FDA approved medication for IBD.
• Who are blind
• With current cancer treatment.
• Pregnant or breastfeeding.
• Work night or rotating shifts.
• Diagnosed with severe psychiatric (bipolar disorder, schizophrenia).
• Neurological conditions affecting the non-dominant hand (due to actigraphy monitoring).
• Those who do not read and write in English
• Those without internet access or email address (due to use of internet surveys).
• Note: We will delay data collection for at least four weeks for those who have had surgery, and 2 weeks for those who have traveled across a time zone or due to daylight savings.

Eligibility last updated 6/9/22. Questions regarding updates should be directed to the study team contact.

• Age birth-100 years, male or female, any race/ethnicity
• Potential participant shall have a confirmed diagnosis of a mitochondrial disease or a suspected diagnosis based on a review of clinical history by a Mitochondrial Disease Biobank working group member using the clinical criteria listed in the table below
• Selected participants shall have at least two documented conditions contained within the minor clinical criteria
  • Minor Criteria
    • Symptoms compatible with a mitochondrial defect
    • Smaller numbers of RRF or widespread electron microscopy abnormalities of mitochondria
    • Antibody-based demonstration of an mito defect or residual activity of an mito complex 20%–30% in a tissue, 30%–40% in a cell line, or 30%–40% in >2 tissues
    • Fibroblast ATP synthesis rates 2–3 SD below mean, or fibroblasts unable to grow in galactose media
    • Nuclear or mtDNA mutation of probable pathogenicity
    • One or more metabolic indicators of impaired metabolic function
• OR one condition in the major criteria with evidence of a condition in the minor criteria, will be considered for inclusion of a participant of appropriate age
  • Major Criteria
    • Multi-systemic symptoms characteristic of mito disorder
    • Progressive clinical course with episodes of exacerbation
    • A family history strongly indicative of an mtDNA mutation
    • Exclusion of other metabolic or non-metabolic disorders
    • >2% ragged red fibers (RRF) in skeletal muscle
    • Cytochrome c oxidase negative fibers (>2-5%) or residual activity of a mito complex <20% in a tissue; <30% in a cell line, or <30% in >2 tissues
    • Fibroblast ATP synthesis rates >3 SD below mean
    • Nuclear or mtDNA mutation of undisputed pathogenicity
• 1st-degree relatives of affected participants (described above) are also invited to participate in the project.
• In addition, samples from participants with one of the following mitochondrial disease diagnosis will be included:
  • Alpers’ progressive sclerosing poliodystrophy 
  • Barth syndrome 
  • CPEO 
  • Dominant optic atrophy
  • Friedriech’s Ataxia
  • Hereditary paraganglioma 
  • Hereditary spastic paraplegia 
  • Kearns-Sayre syndrome Leber hereditary optic neuroretinopathy
  • Leigh and Leigh-like Syndrome 
  • MELAS 
  • MERRF
  • NARP 
  • Pearson syndrome 
  • Wolfram syndrome 
  • Mitochondrial fatty acid oxidation disorder 
  • Urea cycle defect

• Unwilling to provide informed consent
• Unwilling to consent to providing biospecimens to be stored in the biobank for an indefinite amount of time and to be used in future research studies of as yet unknown design
• Does not have a diagnosis of mitochondrial disease or clinical symptoms that are indicative of a potential mitochondrial disease as determined by a chart review by at least one Individualized Medine Biobank for Mitochondrial Disease working-group member

• Non-vulnerable adults who are receiving an endoscopically- placed stent for any indication.

• Pregnancy.
• Imprisoned individuals.
• Institutionalized patients.

• Patients age 0-100 years.
• Clinically diagnosed cardiomyopathy.
• Unaffected biological family members.
• Uunrelated healthy controls.
• IRB# 13-00008 participants.

• Allergy to subcutaneous lidocaine, bupivicaine, or epinephrine. 

Eligibility last updated 11/22/21. Questions regarding updates should be directed to the study team contact.

• Females, age 18 years or older.
• Diagnosed with epithelial ovarian, fallopian tube, or primary peritoneal cancer based on imaging and physician diagnosis.
• Suspected Stage IIIC or IV disease based on clinician staging and imaging.
• Curative intent treatment with platinum-based chemotherapy.
• Planned surgical intervention at some point during treatment course.
• Ability to read English.
• No diagnosed severe cognitive impairment.
• Ability to provide informed consent.
• Ability to utilize technology to watch online modules for the Resilient Living Program.

• Females under 18 years of age.
• Hemiplegia or paraplegia.
• Current pregnancy.

• Stratified balance of age/sex.

• Standard MRI medical/safety exclusion criteria.